Transgene Aktie

0,5460 EUR -0,0550 EUR -9,15 %

15:39:21

STU

0,6110 EUR -0,0290 EUR -4,53 %

04.04.2025

PAR

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.80,62 Mio. EUR

Div. Rendite0,00%

WKN913048

ISINFR0005175080

SymbolTRGNF

Transgene Aktien News

Sortieren:Datum Meistgelesen

01.04.25GlobeNewswireTransgene Appoints Chief Technical Officer (CTO) to Power Future Innovations

11.03.25GlobeNewswireTransgene to Participate in Upcoming Investor Meetings

06.02.25GlobeNewswireTransgene Shares (Euronext Paris: TNG) Eligible for Inclusion in PEA-PME Accounts

WerbungTransgene-Aktie für 0 Euro (zzgl. Spreads) handeln bei finanzen.net zero

21.01.25GlobeNewswireTransgene to Participate in the Biomed Forum Investor Conference

14.01.25GlobeNewswireTransgene Announces Financial Calendar for 2025

07.01.25GlobeNewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2024

07.11.24GlobeNewswireTransgene Reports Business, Pipeline and Financial Update for Q3 2024

07.11.24GlobeNewswireTransgene and NEC Present New Data Confirming Clinical Proof of Principle for Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at SITC 2024

05.11.24GlobeNewswireTransgene and ProBioGen Join Forces to Advance Individualized Cancer Vaccine Development

14.10.24GlobeNewswireTransgene Provides Update on Phase II Trial of Therapeutic Cancer Vaccine TG4001 in Recurrent or Metastatic HPV16-Positive Cervical and Anogenital Cancers

07.10.24GlobeNewswireTransgene to Present a Poster on Updated Data for TG4050 at SITC 2024

24.09.24GlobeNewswire2024 Half-Year Financial Report

24.09.24GlobeNewswireAvailability of Transgene’s Half-Year Financial Report as of June 30, 2024

24.09.24GlobeNewswireTransgene to Report Major Clinical Data before the end of 2024 – Confirmed Financial Visibility until Q4 2025

14.09.24GlobeNewswireTransgene and BioInvent’s Oncolytic Virus BT-001 Shows Promising Antitumor Activity in Ongoing Phase I/IIa Trial in Solid Tumors that Failed Previous Treatments

10.09.24GlobeNewswireTransgene Appoints Two Seasoned Leaders in Oncology to Drive its Next Phase of Innovation

09.09.24GlobeNewswireTransgene and BioInvent to Present Promising Initial Phase I/IIa Data on Oncolytic Virus, BT-001, at ESMO 2024

05.09.24GlobeNewswireTransgene to Participate in HTID Conference and Investor Access Forum in Paris

27.08.24GlobeNewswireTransgene — Preclinical Proof-of-Concept Data of Oncolytic Virus TG6050 published in JITC

22.07.24GlobeNewswireTransgene and BioInvent to Present Poster on Oncolytic Virus, BT-001, at ESMO 2024

10.07.24GlobeNewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of June 30, 2024

03.06.24GlobeNewswireTransgene - First Patient Enrolled in Phase II Part of Randomized Phase I/II Trial Evaluating Lead Cancer Vaccine TG4050 in Head and Neck Cancer

15.05.24GlobeNewswireTransgene’s Combined General Meeting of May 15, 2024

14.05.24GlobeNewswireTransgene provides business and financial update for Q1 2024

24.04.24GlobeNewswireAvailability of Preparatory Documents for the Combined General Meeting of May 15, 2024

11.04.24GlobeNewswireAvailability of Transgene's 2023 Universal Registration Document

09.04.24GlobeNewswireTransgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024

27.03.24GlobeNewswireTransgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025

27.03.24GlobeNewswireTransgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer

18.03.24GlobeNewswireTransgene Announces Upcoming Investor Meetings

06.03.24GlobeNewswireTransgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024

05.03.24GlobeNewswireTransgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050

22.01.24GlobeNewswireTransgene Further Strengthens Management Team with Appointment of James Wentworth as Chief Business Officer

22.01.24GlobeNewswireTransgene Announces Financial Calendar for 2024

08.01.24GlobeNewswireTransgene and NEC Extend their Collaboration to Continue Joint Clinical Development of Neoantigen Cancer Vaccine TG4050

04.01.24GlobeNewswireBalance sheet of the liquidity contract with Natixis Oddo BHF SCA as of December 31, 2023

21.12.23BusinesswireTransgene Announces Upcoming Investor Meetings

05.12.23BusinesswireTransgene Strengthens its Leadership Team to Accelerate its Growth Strategy

07.11.23BusinesswireTransgene Reports Business Update and Q3 2023 Financial Position

10.10.23BusinesswireTransgene and BioInvent - First Patient Treated in Part B of Phase I Trial Assessing the Novel Oncolytic Virus BT-001 in Combination With KEYTRUDA® (pembrolizumab)

Transgene News

Transgene News: auf dieser Seite finden Sie alle Transgene News und Nachrichten zur Transgene Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Transgene News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Transgene News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.